In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Ocular Therapeutix Inc (NASDAQ: OCUL) closed the day trading at $11.41 up 3.16% from the previous closing price of $11.06. In other words, the price has increased by $3.16 from its previous closing price. On the day, 8.12 million shares were traded. OCUL stock price reached its highest trading level at $11.77 during the session, while it also had its lowest trading level at $11.21.
Ratios:
For a better understanding of OCUL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.02 and its Current Ratio is at 10.09. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Chardan Capital Markets on September 15, 2025, initiated with a Buy rating and assigned the stock a target price of $21.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $17.RBC Capital Mkts initiated its Outperform rating on March 18, 2025, with a $17 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 02 ’25 when JEFFREY S. HEIER bought 10,502 shares for $11.04 per share.
PETER KAZUO KAISER bought 9,653 shares of OCUL for $106,516 on Oct 02 ’25. On Sep 02 ’25, another insider, Notman Donald, who serves as the insider of the company, sold 1,066 shares for $12.43 each. As a result, the insider received 13,250 and left with 308,807 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 2417827328 and an Enterprise Value of 1671090432. For the stock, the TTM Price-to-Sale (P/S) ratio is 42.67 while its Price-to-Book (P/B) ratio in mrq is 6.45. Its current Enterprise Value per Revenue stands at 29.491 whereas that against EBITDA is -7.042.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.54, which has changed by 0.20358646 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $13.85, while it has fallen to a 52-week low of $5.78. The 50-Day Moving Average of the stock is -7.23%, while the 200-Day Moving Average is calculated to be 24.07%.
Shares Statistics:
Over the past 3-months, OCUL traded about 2.42M shares per day on average, while over the past 10 days, OCUL traded about 4165600 shares per day. Insiders hold about 16.23% of the company’s shares, while institutions hold 79.34% stake in the company. Shares short for OCUL as of 1757894400 were 15279147 with a Short Ratio of 6.31, compared to 1755216000 on 13079993. Therefore, it implies a Short% of Shares Outstanding of 15279147 and a Short% of Float of 8.8199995.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 3.0 analysts currently analyzing and rating the stock of Ocular Therapeutix Inc (OCUL).The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.31 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.33 and -$1.56 for the fiscal current year, implying an average EPS of -$1.43. EPS for the following year is -$1.41, with 3.0 analysts recommending between -$1.3 and -$1.57.
Revenue Estimates
12 analysts predict $14.57M in revenue for. The current quarter. It ranges from a high estimate of $19M to a low estimate of $12.56M. As of. The current estimate, Ocular Therapeutix Inc’s year-ago sales were $15.43MFor the next quarter, 12 analysts are estimating revenue of $16.23M. There is a high estimate of $24.6M for the next quarter, whereas the lowest estimate is $13.5M.
A total of 12 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $67.8M, while the lowest revenue estimate was $50.3M, resulting in an average revenue estimate of $54.97M. In the same quarter a year ago, actual revenue was $63.72MBased on 12 analysts’ estimates, the company’s revenue will be $65.39M in the next fiscal year. The high estimate is $82.9M and the low estimate is $52.3M.
